E637

E637

SCHEMBL1870685

CCc1occc(=O)c1O.CCc1occc(=O)c1O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
LMNA P02545 1/20 0.55
APP P05067 6/20 0.38
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
MAPK1 P28482 1/20 0.36
FTO Q9C0B1 2/20 0.36
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP12 P39900 1/20 0.35
MMP13 P45452 1/20 0.35
POLB P06746 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALOX5 P09917 1/20 0.32
MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
E637 SCHEMBL41817 1.00 KDM4E (0.55) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL23309786 0.98 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL27635951 0.98 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL6657728 0.98 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL8026696 0.98 KDM4E (0.53) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL14990891 0.93 KDM4E (0.48) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL290806 0.91 LMNA (0.72) KDM4ELMNAAPPGABRA1GABRB2
E637 SCHEMBL11019418 0.89 LMNA (0.70) KDM4ELMNAAPPMAPK1FTO
SCHEMBL9625161 0.84 KDM4E (0.52) KDM4ELMNAAPPMAPK1FTO
SCHEMBL9625506 0.81 KDM4E (0.48) KDM4ELMNAAPPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11062794-B2 Olfactory signature and odorant mixture having the same YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2021-07-13 US disclosed
EP-3416728-A1 METHODS OF FORMING A SLURRY WITH MICROCAPSULES FORMED FROM PHOSPHATE ESTERS AND MULTIVALENT IONS The Procter and Gamble Company (US) 2018-12-26 EP disclosed
EP-3399960-A1 ANTIPERSPIRANT COMPOSITION The Procter and Gamble Company (US) 2018-11-14 EP disclosed
US-20180253534-A1 OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2018-09-06 US disclosed
EP-3250179-A1 STARCH BENEFIT AGENT DELIVERY VEHICLE The Procter and Gamble Company (US) 2017-12-06 EP disclosed
WO-2017120152-A1 ANTIPERSPIRANT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2017-07-13 WO disclosed
WO-2017120149-A1 STARCH BENEFIT AGENT DELIVERY VEHICLE THE PROCTER & GAMBLE COMPANY (US) 2017-07-13 WO disclosed
WO-2017120151-A1 METHODS OF FORMING A SLURRY WITH MICROCAPSULES FORMED FROM PHOSPHATE ESTERS AND MULTIVALENT IONS THE PROCTER & GAMBLE COMPANY (US) 2017-07-13 WO disclosed
EP-2496682-A1 DELIVERY PARTICLE The Procter & Gamble Company (US) 2012-09-12 EP disclosed
WO-2011056935-A1 DELIVERY PARTICLE THE PROCTER & GAMBLE COMPANY (US) 2011-05-12 WO disclosed
US-20090257973-A1 MALODOR REDUCING COMPOSITION, FRAGRANCE COMPOSITION AND PRODUCT COMPRISING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257973-A1 MALODOR REDUCING COMPOSITION, FRAGRANCE COMPOSITION AND PRODUCT COMPRISING THE SAME AKR1C4, AKR1C3, AKR1C1 KDM4E 287/4885LMNA 1684/4885APP 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.